Hugel Presents at 'JP Morgan Healthcare Conference' for Second Consecutive Year

[Asia Economy Reporter Hyunseok Yoo] Hugel, a global total medical aesthetic specialist company, announced on the 5th that it will participate in the '39th J.P. Morgan Healthcare Conference,' held online in a non-face-to-face format from the 11th to the 14th.

Participating as a presenter for the second consecutive year at the J.P. Morgan Healthcare Conference, Hugel will present its '2020 Performance and 2025 Vision' through the 'Emerging Market' track at 9:30 PM (Korean time) on the 13th.

During the conference, Hugel will also hold one-on-one meetings with major overseas institutional investors. Key executives, including CEO and Executive Officer Son Ji-hoon, Vice President and Head of Development Division Lee Chang-jin, and Executive Director of the Communications Business Division Noh Ji-hye, will attend the presentation in large numbers.

Hugel was the first in Korea and the fourth in the world to obtain product approval for the botulinum toxin formulation 'Letybo' from China. Recognized for its company's remarkable growth potential, Hugel has been invited again as a presenter following last year.

On this day, Hugel will introduce the competitiveness of a company that not only maintains an unshakable No. 1 position in the domestic market but also has rapidly emerged as a global key player by successfully entering the Chinese market. It will also reveal its 2025 vision and a three-year growth strategy from 2021 to 2023 to achieve it.

This year, with plans to obtain European sales approval for botulinum toxin and submit a BLA in the United States, Hugel will focus on its global business vision. As this is the first year to visibly confirm its achievements in entering the Chinese market, it plans to present an in-depth market expansion strategy.

Hugel will also unveil a blueprint for becoming a global leader in the medical aesthetic field. As the world's first company capable of manufacturing and selling three products?botulinum toxin, HA filler, and lifting threads?it will explain its corporate growth vision through various R&D pipelines, open innovation strategies, and expansion of production facilities.

A Hugel official said, "We are pleased to be invited again as a presenter after announcing major plans such as Chinese approval and European BLA submission at last year's J.P. Morgan Healthcare Conference and achieving them," adding, "We will actively promote Hugel's corporate value, which has grown solidly based on reliable product power, and the company's will and growth potential toward becoming a global player to the market."

This content was produced with the assistance of AI translation services.